docetaxel anhydrous has been researched along with aee 788 in 2 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (aee 788) | Trials (aee 788) | Recent Studies (post-2010) (aee 788) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 83 | 3 | 34 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | aee 788 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.002 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.004 | |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | 0.0153 | |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | 0.74 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.059 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.002 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.077 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bischoff, FZ; Coleman, RL; Gershenson, DM; Han, LY; Heymach, JV; Jaffe, RB; Kamat, AA; Kim, TJ; Landen, CN; Lin, YG; Lu, C; Merritt, WM; Sood, AK; Thaker, PH | 1 |
2 other study(ies) available for docetaxel anhydrous and aee 788
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Survival; DNA, Neoplasm; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Purines; Taxoids | 2007 |